Jonathan Freve Biography and Net Worth

CFO of Damora Therapeutics, Inc. Common Stock

Jon Freve brings more than 20 years of financial experience in the biotechnology sector. Prior to joining Galecto, Jon served as CFO and Treasurer of Spring Bank Pharmaceuticals, a publicly listed clinical stage biotechnology company, and before that, as Sr. Director of Finance at Santaris Pharma. He began his career at the Financial Accounting Standards Board (FASB) and PricewaterhouseCoopers, where he worked in audit and transaction services. Jon has worked on several successful initial public offerings, secondary offerings, mergers and acquisitions and is a certified public accountant. He holds a Bachelor’s degree in Business Administration from the University of Massachusetts Amherst.

What is Jonathan Freve's net worth?: The estimated net worth of Jonathan Freve is at least $2.07 thousand as of June 23rd, 2021. Mr. Freve owns 80 shares of Damora Therapeutics, Inc. Common Stock stock worth more than $2,066 as of April 11th. This net worth evaluation does not reflect any other investments that Mr. Freve may own. Learn More about Jonathan Freve's net worth.
How do I contact Jonathan Freve?: The corporate mailing address for Mr. Freve and other Damora Therapeutics, Inc. Common Stock executives is GALECTO BIOTECH AB OLE MAALOES VEJ3, COPENHAGEN G7, DK-2200. Damora Therapeutics, Inc. Common Stock can also be reached via phone at 45-7070-5210 and via email at [email protected]. Learn More on Jonathan Freve's contact information.
Has Jonathan Freve been buying or selling shares of Damora Therapeutics, Inc. Common Stock?: Jonathan Freve has not been actively trading shares of Damora Therapeutics, Inc. Common Stock during the last ninety days. Most recently, on Friday, December 3rd, Jonathan Freve bought 160 shares of Damora Therapeutics, Inc. Common Stock stock. The stock was acquired at an average cost of $62.25 per share, with a total value of $9,960.00. Learn More on Jonathan Freve's trading history.
Who are Damora Therapeutics, Inc. Common Stock's active insiders?: Damora Therapeutics, Inc. Common Stock's insider roster includes Jonathan Freve (CFO), Bertil Lindmark (Insider), Hans Schambye (CEO), and Garrett Winslow (General Counsel). Learn More on Damora Therapeutics, Inc. Common Stock's active insiders.
Are insiders buying or selling shares of Damora Therapeutics, Inc. Common Stock?: In the last year, insiders at the sold shares 4 times. They sold a total of 1,717 shares worth more than $20,838.98. The most recent insider tranaction occured on January, 2nd when CEO Hans T Schambye sold 700 shares worth more than $14,966.00. Insiders at Damora Therapeutics, Inc. Common Stock own 10.5% of the company. Learn More about insider trades at Damora Therapeutics, Inc. Common Stock.
Information on this page was last updated on 1/2/2026.

Jonathan Freve Insider Trading History at Damora Therapeutics, Inc. Common Stock

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/3/2021	Buy	160	$62.25	$9,960.00
11/8/2021	Buy	120	$85.00	$10,200.00
8/18/2021	Buy	120	$98.00	$11,760.00
6/23/2021	Buy	80	$118.50	$9,480.00	80

Jonathan Freve Buying and Selling Activity at Damora Therapeutics, Inc. Common Stock

Damora Therapeutics, Inc. Common Stock Company Overview

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Today's Range

Now: $25.82

$25.55

$27.88

50 Day Range

MA: $26.81

$18.14

$32.30

2 Week Range

Now: $25.82

$2.14

$38.33

Volume

287,217 shs

Average Volume

276,563 shs

Market Capitalization

$1.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.59